Combinations of Pharmacologic Smoking Cessation Treatments
Phase 1
Completed
- Conditions
- Smoking
- Registration Number
- NCT00018187
- Lead Sponsor
- US Department of Veterans Affairs
- Brief Summary
The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which bupropion and mecamylamine enhance nicotine patch efficacy in smoking cessation?
How does the bupropion-mecamylamine-nicotine patch combination compare to standard monotherapies in smoking cessation rates and relapse prevention?
Which biomarkers are associated with improved response to combined bupropion, mecamylamine, and nicotine replacement therapy in tobacco addiction?
What are the potential adverse events and management strategies for triple therapy with bupropion, mecamylamine, and nicotine patches in nicotine-dependent patients?
Are there alternative combination therapies targeting nicotinic acetylcholine receptors for smoking cessation compared to the bupropion-mecamylamine-nicotine approach in NCT000187?
Trial Locations
- Locations (1)
VA Greater Los Angeles Healthcare System
🇺🇸Los Angeles, California, United States
VA Greater Los Angeles Healthcare System🇺🇸Los Angeles, California, United States